All Title Author
Keywords Abstract

Publish in OALib Journal
ISSN: 2333-9721
APC: Only $99

ViewsDownloads

Relative Articles

Effects of omacor<sup>® </sup>on left ventricular remodelling consecutive to post myocardial infarction special issue-myocardial infarction

Effect of Omacor on HRV parameters in patients with recent uncomplicated myocardial infarction – A randomized, parallel group, double-blind, placebo-controlled trial: study design [ISRCTN75358739]

Value of C-Reactive Protein in Predicting Left Ventricular Remodelling in Patients with a First ST-Segment Elevation Myocardial Infarction

Predictors of Myocardial Infarction and the Features of Postinfarction Remodelling in Patients with Chronic Obstructive Pulmonary Disease

Ultrasound-Mediated Stimulation of Microbubbles after Acute Myocardial Infarction and Reperfusion Ameliorates Left-Ventricular Remodelling in Mice via Improvement of Borderzone Vascularization

Long-Term Left Ventricular Remodelling in Rat Model of Nonreperfused Myocardial Infarction: Sequential MR Imaging Using a 3T Clinical Scanner

Effectiveness of sertraline in treatment of depression in a consecutive sample of patients with acute myocardial infarction: six month prospective study on outcome

MYOCARDIAL INFARCTION

Impact of thrombolytic therapy on the incidence of complex ventricular arrhythmias in the late hospital phase of the acute myocardial infarction: Relation with the long-lasting left ventricle remodeli

Effectiveness of primary angioplasty in the treatment of acute myocardial infarction. Analysis of in-hospital and late outcomes in 135 consecutive cases

Effectiveness of primary angioplasty in the treatment of acute myocardial infarction. Analysis of in-hospital and late outcomes in 135 consecutive cases

More...

Effects of omacor® on left ventricular remodelling consecutive to post myocardial infarction special issue-myocardial infarction

DOI: 10.4236/wjcd.2013.35A007, PP. 40-44

Keywords: Left Ventricular Remodelling, Myocardial Infarction, OMACOR®

Full-Text   Cite this paper   Add to My Lib

Abstract:

Ventricular remodelling is the main trigger of the development of heart failure. Therefore, the reduction of structural remodelling is known to prevent the development of heart failure. The aim of the present study was to investigate the effects of OMACOR?, a well known mixture of EPA and DHA in an experimental model of heart failure induced by occlusion of left descending coronary artery and the reperfusion within 2 months. After a long term treatment of 2 months; OMACOR? (100 mg/kg) statistically significantly reduced the expansion of infarcted zone (35% ± 4%, P < 0.05, n = 9, versus 45% ± 3% in the vehicle group). The phosphorylation of Cx43 as biomarker of the cardiac remodelling was visualised by immunofluorescence in rat’s heart at the end of the study. In the vehicle-infarcted group, a significant de-phosphorylation of Cx43 was observed (8.2 ± 1.0 u.a, n = 8 compared to 11.8 ± 1.3 u.a in the sham group, n = 9) confirming a remodelling process in the infarcted group. In the group treated with OMACOR?,the de-phosphorylation of Cx43 was no longer observed compared to the sham group (16.4 ± 2.9 u.a, n = 9, NS). The present results demonstrate that a long term treatment with OMA-COR? reduced the infarcted size in experimental models of heart failure and that these anti-remodelling effects are due at least in part by resynchronizing the gap junction activity.


References

[1]  Bull, D.A., Bailey, S.H., Rentz, J.J., Zebrack, J.S., Lee, M., Litwin, S.E. and Kim, S.W. (2003) Effect of Terplex/ VEGF165 gene therapy on left ventricular function and structure following myocardial infarction. VEGF gene therapy for myocardial infarction. Journal of Control Release, 93, 175-181. doi:10.1016/j.jconrel.2003.06.002
[2]  Hu, N., Straub, C.M., Garzarelli, A.A., Sabey, K.H., Yockman, J.W. and Bull, D.A. (2010) Ligation of the left circumflex coronary artery with subsequent MRI and histopathology in rabbits. Journal of the American Association for Laboratory Animal Science, 49, 838-844.
[3]  Yockman, J.W., Kastenmeier, A., Erickson, H.M., Brumbach, J.G., Whitten, M.G., Albanil, A., Li, D.Y., Kim, S.W. and Bull, D.A. (2008) Novel polymer carriers and gene constructs for treatment of myocardial ischemia and infarction. Journal of Control Release, 132, 260-266. doi:10.1016/j.jconrel.2008.06.024
[4]  Chen, J., Song, S.K., Liu, W., McLean, M., Allen, J.S., Tan, J., Wickline, S.A. and Yu, X. (2003) Remodelling of cardiac fiber structure after infarction in rats quantified with diffusion tensor MRI. American Journal of Physiology—Heart and Circulatory Physiology, 285, H946-H954.
[5]  Cleutjens, J.P., Blankesteijn, W.M., Daemen, M.J. and Smits, J.F. (1999) The infarcted myocardium: Simply dead tissue, or a lively target for therapeutic interventions? Cardiovascular Research, 44, 232-241. doi:10.1016/S0008-6363(99)00212-6
[6]  Marchioli, R., Barzi, F., Bomba, E., Chieffo, C., Di Gregorio, D., Di Mascio, R., Franzosi, M.G., Geraci, E., Levantesi, G., Maggioni, A.P., Mantini, L., Marfisi, R.M., Mastrogiuseppe, G., Mininni, N., Nicolosi, G.L., Santini, M., Schweiger, C., Tavazzi, L., Tognoni, G., Tucci, C., Valagussa, F. and GISSI-Prevenzione Investigators (2002) Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation, 105, 1897-903. doi:10.1161/01.CIR.0000014682.14181.F2
[7]  Tavazzi, L., Maggioni, A.P., Marchioli, R., Barlera, S., Franzosi, M.G., Latini, R., Lucci, D., Nicolosi, G.L., Porcu, M. and Tognoni, G. (2008) Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet, 372, 1223-1230. doi:10.1016/S0140-6736(08)61239-8
[8]  Duda, M.K., O’Shea, K.M., Tintinu, A., Xu, W., Khairallah, R.J., Barrows, B.R., Chess, D.J., Azimzadeh, A.M., Harris, W.S., Sharov, V.G., Sabbah, H.N. and Stanley, W.C. (2009) Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. Cardiovascular Research, 81, 319-327. doi:10.1093/cvr/cvn310
[9]  Den Ruijter, H.M., Verkerk, A.O., Schumacher, C.A., Houten, S.M., Belterman, C.N., Baartscheer, A., Brouwer, I.A., van Bilsen, M., de Roos, B. and Coronel, R. (2012) A diet rich in unsaturated fatty acids prevents progression toward heart failure in a rabbit model of pressure and volume overload. Circulation: Heart Failure, 5, 376-384. doi:10.1161/CIRCHEARTFAILURE.111.963116
[10]  Kromhout, D., Yasuda, S., Geleijnse, J.M. and Shimokawa, H. (2012) Fish oil and omega-3 fatty acids in cardiovascular disease: Do they really work? European Heart Journal, 33, 436-443. doi:10.1093/eurheartj/ehr362
[11]  Rucker-Martin, C., Milliez, P., Tan, S., Decrouy, X., Recouvreur, M., Vranckx, R., Delcayre, C., Renaud, J.F., Dunia, I., Segretain, D. and Hatem, S.N. (2006) Chronic hemodynamic overload of the atria is an important factor for gap junction remodelling in human and rat hearts. Cardiovascular Research, 72, 69-79. doi:10.1016/j.cardiores.2006.06.016
[12]  Duda, M.K., O’Shea, K.M., Stanley, W.C. (2009) w-3 polyunsaturated fatty acid supplementation for the treatment of heart failure: Mechanisms and clinical potential. Cardiovascular Research, 84, 33-41. doi:10.1093/cvr/cvp169
[13]  Adkins, Y. and Kelley, D.S. (2010) Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. The Journal of Nutritional Biochemistry, 21, 781-792. doi:10.1016/j.jnutbio.2009.12.004
[14]  Billman, G.E., Nishijima, Y., Belevych, A.E., Terentyev, D., Xu, Y., Haizlip, K.M., Monasky, M.M., Hiranandani, N., Harris, W.S., Gyorke, S., Carnes, C.A. and Janssen, P.M.L. (2010) Effects of dietary omega-3 fatty acids on ventricular function in dogs with healed myocardial infarctions: in vivo and in vitro studies. American Journal of Physiology—Heart and Circulatory Physiology, 298, H1219-H1228. doi:10.1152/ajpheart.01065.2009
[15]  Segretain, D. and Falk, M.M. (2004) Regulation of connexin biosynthesis, assembly, gap junction formation, and removal. Biochimica et Biophysica Acta, 1662, 3-21.

Full-Text

comments powered by Disqus